Lunit Goes Public

Lunit, a global AI-based cancer solutions provider invested by Legend Capital, was listed on the KOSDAQ market.

Founded in 2013 and led by Brandon Suh, CEO, Lunit is a an artificial intelligence technology solution provider, mainly focusing on developing medical software to assist physicians in the realm of tumor diagnosis and treatment. Lunit’s flagship products are Lunit INSIGHT and Lunit SCOPE. Lunit INSIGHT is an AI-powered image screening solution, that detects and classifies chest abnormalities and breast cancer. Lunit SCOPE is an AI biomarker for immunotherapy, providing therapy response information that can critically affect treatment outcomes for cancer patients. 

The company’s annual revenue grew by over 460% in 2021 since its initial product commercialization in 2019. As of now, Lunit’s image diagnostic products have been certified by 42 countries/regions, including FDA, CE, and KFDA. Lunit will keep expanding into the global market through cooperation with international giants like GE Healthcare, Fujifilm, and Philips, etc.

At present, “Lunit INSIGHT CXR Triage” and “Lunit INSIGHT MMG” have been certified by the U.S. Food and Drug Administration (FDA) by the end of 2021, and the company will continue to expand the global market by obtaining Medical Device Single Audit Program (MDSAP) certification in the US, Canada, Japan, Australia and Brazil, etc.

FinSMEs

24/07/2022